European Medicines Agency recommends approval of first vaccine for meningitis B

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for Bexsero, a new vaccine intended for the immunisation of individuals over two months of age against invasive meningococcal disease caused by Neisseria meningitis group B.

There is currentlyno authorised vaccine available in the European Union (EU) for bacterial meningitis caused by Neisseria meningitis group B.

Ver: vacuna antimeningocócica B